Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Accumulated Expenses (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of Accumulated Expenses data on record, last reported at $116.3 million in Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 74.14% year-over-year to $116.3 million; the TTM value through Dec 2025 reached $116.3 million, up 74.14%, while the annual FY2025 figure was $116.3 million, 74.14% up from the prior year.
  • Accumulated Expenses reached $116.3 million in Q4 2025 per ARQT's latest filing, up from $65.8 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $116.3 million in Q4 2025 and bottomed at $20.0 million in Q1 2022.
  • Average Accumulated Expenses over 5 years is $47.5 million, with a median of $30.8 million recorded in 2023.
  • Peak YoY movement for Accumulated Expenses: grew 19.38% in 2023, then skyrocketed 95.8% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $25.5 million in 2021, then dropped by 21.73% to $20.0 million in 2022, then skyrocketed by 40.05% to $28.0 million in 2023, then skyrocketed by 138.59% to $66.8 million in 2024, then skyrocketed by 74.14% to $116.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $116.3 million in Q4 2025, $65.8 million in Q1 2025, and $66.8 million in Q4 2024.